Prostate cancer, Secondary cancers
Open
Phase 3
This trial is comparing a new drug called BNT324 with for prostate cancer.
It is for men with metastatic castration resistant prostate cancer (mCRPC). This means that the cancer has:
spread to other parts of the body (advanced prostate cancer), and
got worse despite having hormone treatment
Recruitment start: 30 July 2026
Recruitment end: 31 May 2028
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Johann de Bono
BioNTech SE
Last reviewed: 07 Oct 2026
CRUK internal database number: 20192
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Connect with other people affected by cancer and share your experiences.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
